Analyzing Cardiac Biotech Solutions (OTCMKTS:CBSC) and ADMA Biologics (NASDAQ:ADMA)

Cardiac Biotech Solutions (OTCMKTS:CBSC) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Earnings and Valuation

This table compares Cardiac Biotech Solutions and ADMA Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiac Biotech Solutions	$140,000.00	35.45	N/A	N/A	N/A
ADMA Biologics	$510.17 million	4.27	$146.93 million	$0.60	15.26

ADMA Biologics has higher revenue and earnings than Cardiac Biotech Solutions.

Volatility & Risk

Cardiac Biotech Solutions has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Cardiac Biotech Solutions and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiac Biotech Solutions	N/A	N/A	N/A
ADMA Biologics	28.80%	37.52%	27.87%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cardiac Biotech Solutions and ADMA Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiac Biotech Solutions	0	0	0	0	0.00
ADMA Biologics	0	2	0	2	3.00

ADMA Biologics has a consensus target price of $32.00, suggesting a potential upside of 249.54%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Cardiac Biotech Solutions.

Institutional and Insider Ownership

75.7% of ADMA Biologics shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats Cardiac Biotech Solutions on 9 of the 11 factors compared between the two stocks.

About Cardiac Biotech Solutions

CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.